Form 4: Treace Medical Concepts Executive Sean Scanlan Reports Stock Disposals

Sean Scanlan, Chief Innovation Officer of Treace Medical Concepts, reports disposing of common stock to cover tax obligations related to restricted stock units.

Summary

• On March 8, 2024, Sean Scanlan, Chief Innovation Officer of Treace Medical Concepts, disposed of 389 shares of common stock to cover tax obligations.
• The disposal was executed at a price of $0 per share.
• Following this transaction, Scanlan directly owns 96,820 shares, including 95,681 restricted stock units.
• On March 10, 2024, Scanlan disposed of 1,396 shares of common stock for tax obligations.
• Following this transaction, Scanlan directly owns 95,424 shares, including 94,285 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock disposals for tax purposes. It doesn't inherently indicate positive or negative sentiment regarding the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions.

Stakeholder Impact

• The stock disposals by an executive could be perceived negatively by some shareholders, although these transactions are common for covering tax obligations related to equity compensation.

Key Dates